Brachytherapy Market to Reach Billion by 2035, Growing at a CAGR of 6.1%
Brachytherapy market is expected to witness significant growth through 2035, driven by the rising prevalence of cancer cases worldwide and increasing adoption of minimally invasive radiation therapies. Growing incidences of breast cancer, gynecological cancer, prostate cancer, skin cancer, and brain cancer are accelerating the demand for advanced brachytherapy procedures. In addition, technological advancements in high-dose rate (HDR) brachytherapy systems, improved treatment precision, reduced side effects, and shorter recovery times are further supporting market growth across hospitals and oncology centers globally.
Browse the full report description of “Brachytherapy Market Size, Share & Trends Analysis by Indication (Breast Cancer, Gynecological Cancer, Prostate Cancer, Skin Cancer, Brain Cancer, and Others), by Type (Low-Dose Rate and High-Dose Rate), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/brachytherapy-market
Elekta AB expands Gamma Knife radiosurgery applications (2025)
Elekta AB received U.S. FDA 510(k) clearance for expanded use of its Leksell Gamma Knife system for the treatment of refractory drug-resistant mesial temporal lobe epilepsy. The approval strengthens the company’s precision radiation therapy portfolio and broadens the clinical applications associated with stereotactic and internal radiation oncology procedures. The expanded indication is expected to support increased adoption of non-invasive radiosurgery technologies for neurological disorders, while also reinforcing Elekta’s position in advanced radiation treatment solutions and image-guided therapy systems.
GT Medical Technologies achieves major GammaTile® treatment milestone (2025)
GT Medical Technologies reported that more than 2,000 patients have been treated with its FDA-cleared GammaTile® therapy across over 200 cancer centers and hospitals in the United States. The milestone highlights the growing adoption of implantable Cesium-131 based brachytherapy solutions for brain tumor treatment and reflects increasing demand for localized radiation delivery technologies in oncology. The company’s GammaTile® platform combines surgically targeted radiation with immediate post-operative treatment, helping improve precision therapy approaches for patients with recurrent and newly diagnosed brain tumors.
About OMR Global
OMR Global is a market intelligence and strategic consulting firm specializing in growth advisory, competitive intelligence, and AI-enabled business research across global B2B industries.
The company supports enterprises, investors, and technology providers with actionable insights for market entry, investment analysis, procurement strategy, commercialization, and business expansion. OMR Global combines industry expertise, primary research, analytics, and digital intelligence tools to help organizations navigate evolving market landscapes and identify growth opportunities.
OMR Digital Offerings
- Pulse Intelligence Platform – AI-powered market intelligence suite designed to deliver analyst-grade insights faster and more efficiently. Built on 12+ years of research expertise and enhanced with AI-driven analytics, Pulse helps organizations transform large volumes of market and company data into actionable intelligence within hours instead of weeks. Trusted by Fortune 500 enterprises, global investment banks, strategy consultancies, and PE & VC firms, Pulse supports strategic decision-making across investment evaluation, competitive benchmarking, AI readiness, and market positioning.
Other Offerings
- Lead Generation – Verified B2B prospect data, ICP targeting, and intent-based sales intelligence
- RFx Support – End-to-end RFP, RFI, and RFQ support with vendor benchmarking and evaluation frameworks
OMR Global delivers data-driven intelligence solutions designed to support strategic decision-making, operational efficiency, and long-term business growth.
To find out more, visit www.omrglobal.com
Contact:
Mr. Anurag Tiwari
305-308, Commerce House, Janjeerwala Square,
Indore, Madhya Pradesh 452001
India
+91-780-304-0404